tiprankstipranks
Trending News
More News >
Japan Medical Dynamic Marketing, Inc. (JP:7600)
:7600
Japanese Market
Advertisement

Japan Medical Dynamic Marketing, Inc. (7600) AI Stock Analysis

Compare
0 Followers

Top Page

JP:7600

Japan Medical Dynamic Marketing, Inc.

(7600)

Rating:56Neutral
Price Target:
¥565.00
▲(2.91% Upside)
The overall stock score is primarily influenced by the company's financial performance, which shows stable revenue growth but profitability challenges. Technical analysis indicates a bearish trend, and valuation is impacted by negative earnings. The dividend yield provides some support, but overall, the stock faces significant challenges.

Japan Medical Dynamic Marketing, Inc. (7600) vs. iShares MSCI Japan ETF (EWJ)

Japan Medical Dynamic Marketing, Inc. Business Overview & Revenue Model

Company DescriptionJapan Medical Dynamic Marketing, INC. develops, manufactures, imports, and sells medical devices in Japan and the United States. The company provides trauma devices, including nails, screws, plates, and other products surgically implanted in the fracture site; joint prostheses, which replaces natural joints and restores functions damaged or lost due to disease or injury; spinal fixation devices for the use in spinal instability surgery; and artificial bone fillers for the treatment of bone fractures, tumors, and other defects. It offers its products to medical professionals and hospitals. The company was incorporated in 1973 and is headquartered in Tokyo, Japan.
How the Company Makes MoneyJapan Medical Dynamic Marketing, Inc. generates revenue through the sale of its medical devices and instruments to hospitals, clinics, and healthcare facilities. The company earns money by leveraging its expertise in the medical field to offer innovative and effective solutions for orthopedic and surgical needs. Key revenue streams include direct sales of products, partnerships with healthcare providers, and potentially ongoing service or maintenance contracts for its equipment. Additionally, strategic collaborations with other medical companies and participation in government healthcare initiatives may also contribute to its earnings.

Japan Medical Dynamic Marketing, Inc. Financial Statement Overview

Summary
The company shows stable revenue growth but faces profitability challenges due to negative net income in 2025. A robust balance sheet with low leverage is a positive factor, but negative free cash flow indicates cash management issues.
Income Statement
65
Positive
The company experienced a moderate revenue growth rate over recent years, with a notable increase from 2024 to 2025. However, the net profit margin turned negative in 2025, indicating profitability challenges. Gross profit margins have remained relatively stable, but declining EBIT and EBITDA margins suggest rising operational costs.
Balance Sheet
72
Positive
The balance sheet shows a strong equity base with a healthy equity ratio, demonstrating financial stability. The debt-to-equity ratio is relatively low, indicating conservative leverage. However, a decrease in stockholders' equity in 2025 could be a concern if it continues.
Cash Flow
60
Neutral
Free cash flow has fluctuated, turning negative in 2025, which might impact liquidity. The operating cash flow to net income ratio shows adequate cash conversion, but the negative free cash flow raises concerns about the company's ability to fund operations and growth without external financing.
BreakdownMar 2025Mar 2024Mar 2023Mar 2022Mar 2021
Income Statement
Total Revenue25.11B23.18B21.31B19.19B16.74B
Gross Profit14.21B14.76B13.99B12.99B11.42B
EBITDA1.40B3.27B3.35B4.21B3.47B
Net Income-461.80M1.27B1.42B2.14B1.66B
Balance Sheet
Total Assets33.67B31.49B29.43B27.34B25.19B
Cash, Cash Equivalents and Short-Term Investments3.18B2.32B2.80B2.59B2.47B
Total Debt3.29B1.49B1.87B1.85B3.09B
Total Liabilities8.93B5.88B6.14B5.85B6.48B
Stockholders Equity24.68B25.51B23.16B21.39B18.63B
Cash Flow
Free Cash Flow-504.10M302.45M870.67M1.53B1.23B
Operating Cash Flow1.05B2.10B2.19B3.11B2.60B
Investing Cash Flow-1.67B-1.80B-1.48B-1.75B-1.35B
Financing Cash Flow1.49B-840.71M-514.78M-1.29B-1.31B

Japan Medical Dynamic Marketing, Inc. Technical Analysis

Technical Analysis Sentiment
Positive
Last Price549.00
Price Trends
50DMA
553.32
Negative
100DMA
551.97
Negative
200DMA
575.78
Negative
Market Momentum
MACD
-3.35
Positive
RSI
50.58
Neutral
STOCH
45.24
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:7600, the sentiment is Positive. The current price of 549 is above the 20-day moving average (MA) of 547.65, below the 50-day MA of 553.32, and below the 200-day MA of 575.78, indicating a neutral trend. The MACD of -3.35 indicates Positive momentum. The RSI at 50.58 is Neutral, neither overbought nor oversold. The STOCH value of 45.24 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:7600.

Japan Medical Dynamic Marketing, Inc. Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
56
Neutral
¥14.38B10.23
2.81%4.84%-148.94%
51
Neutral
$7.37B0.24-62.86%2.36%15.01%-2.64%
$177.63M-184.59%
78
Outperform
¥8.88B11.89
3.74%3.38%88.65%
77
Outperform
¥13.46B10.64
2.05%13.54%78.47%
75
Outperform
¥8.31B10.75
2.04%11.24%53.32%
74
Outperform
¥16.45B15.78
3.56%5.92%8.59%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
JP:7600
Japan Medical Dynamic Marketing, Inc.
544.00
-190.54
-25.94%
DMTRF
3-D Matrix
1.50
0.39
35.14%
JP:5187
Create Medic Co., Ltd.
990.00
80.54
8.86%
JP:6678
Techno Medica Co., Ltd.
1,910.00
278.02
17.04%
JP:7792
Colan Totte.Co.,Ltd.
1,536.00
615.87
66.93%
JP:7963
Koken Ltd.
1,684.00
174.96
11.59%

Japan Medical Dynamic Marketing, Inc. Corporate Events

Japan Medical Dynamic Marketing Reports Q1 Financial Decline Amidst Market Challenges
Jul 30, 2025

Japan Medical Dynamic Marketing, Inc. reported a decline in its financial performance for the first quarter of the fiscal year ending March 2026, with significant drops in net sales, operating profit, and profit attributable to owners of the parent compared to the previous year. Despite the downturn, the company maintains a strong capital adequacy ratio and has not revised its financial forecasts, suggesting a cautious optimism about future performance.

Japan Medical Dynamic Marketing Affirms Independence Amid Mitsui Chemicals Alliance
Jun 24, 2025

Japan Medical Dynamic Marketing, Inc. announced its relationship with Mitsui Chemicals, Inc., highlighting a capital and business alliance aimed at expanding their operations in the medical device field. Despite Mitsui Chemicals’ significant voting rights, Japan Medical Dynamic Marketing maintains operational independence, ensuring no restrictions on its business activities, which supports its strategic growth and industry positioning.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Aug 08, 2025